Hilleman Laboratories, an organisation with a mission to develop affordable vaccines and biologics against infectious diseases with unmet medical need, officially opened its US$20 million (SGD$27 million) ACES current Good Manufacturing Practices (cGMP) facility in Singapore today. The opening ceremony was graced by Mr. Ong Ye Kung, Singapore’s Minister for Health, and attended by Jacqueline Poh, Managing Director, Economic Development Board, Mr. Sanat Chattopadhyay, Chairman of Hilleman Board of Directors, members of MSD and the Wellcome Trust, UK.
The 30,000-square-foot manufacturing facility at Depot Road, which broke ground in February 2022, is now fully operational and can produce affordable, high-value vaccines and biologics that comply with local and international regulations. The facility will primarily focus on supplying clinical trial materials for development of up to the Phase II stage and has the built-in capability to pivot to producing vaccines and biologics for Singapore’s use during future pandemics and public health emergencies.
The ACES cGMP facility is designed to achieve agile manufacturing, through a highly compact and configurable design, with end-to-end production capabilities. Portable, skid-mounted, single-use systems allow the facility’s manufacturing model to remain platform-agnostic and product-independent, thus enabling production to remain agile and easily adaptable for future or emergency needs without significant disruption to ongoing operations. Additionally, the facility is also capable of parallel production in controlled isolated suites and is supported by in-process testing to rapidly generate test results to facilitate GMP decision-making.
